<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We report here the first case with Diamond-Blackfan <z:hpo ids='HP_0001903'>anemia</z:hpo> (<z:chebi fb="28" ids="35299">DBA</z:chebi>) who responded to rituximab </plain></SENT>
<SENT sid="1" pm="."><plain>The patient is an 8-yr-old Japanese girl with refractory <z:chebi fb="28" ids="35299">DBA</z:chebi> accompanied by complex <z:hpo ids='HP_0002564'>congenital heart disease</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>She received two doses of rituximab, 375 mg/m(2)/wk </plain></SENT>
<SENT sid="3" pm="."><plain>She became transfusion independent 6 months after the treatment without any serious side effect </plain></SENT>
<SENT sid="4" pm="."><plain>However, after 8 months of transfusion-free period, her condition returned to the pretreatment level with recovery of peripheral B cells </plain></SENT>
<SENT sid="5" pm="."><plain>Rituximab may be a successful therapy for refractory <z:chebi fb="28" ids="35299">DBA</z:chebi> where B cells play a crucial role in the pathogenesis of the severe <z:hpo ids='HP_0001903'>anemia</z:hpo> </plain></SENT>
</text></document>